Peter Soukas

Wednesday, January 23, 2013

DISCUSSION FORUM

14:30 – 15:30  Why I do what I do in SFA occlusive disease?
               supported with an unrestricted educational grant by Gore & Associates
               CHAIRMAN:  
               Peter Soukas
               DISCUSSANT:
               Gerrit Krupski-Berdien
               Ulf Teichgräber

15:05 – 15:15  How do I treat in-stent restenosis in SFA?

15:15 – 15:30  Discussion and conclusion

14:55 – 15:05  When do I use BMS? Will new stent designs provide better results and value?
               Ulf Teichgräber

14:45 – 14:55  What do most recent trials suggest?
               Gerrit Krupski-Berdien

14:35 – 14:45  How do I treat de-novo lesions?
               Peter Soukas

14:30 – 14:35  Introduction by the chairman

We are asking all faculty members to strictly respect the given time limits.
Thursday, January 24, 2013

DISCUSSION FORUM

09:00 – 10:00  VIVA @ LINC: The future of renal revascularization

CHAIRMAN:
Michael Jaff
Sean Lyden

DISCUSSANT:
Sean Lyden
Peter Soukas
Sumaira Macdonald
Chris Metzger
Krishna Rocha-Singh

09:00 – 10:00  Case presentation

We are asking all faculty members to strictly respect the given time limits.
**Thursday, January 24, 2013**

**MAIN ARENA 1**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:30</td>
<td>Symposium: Unique technologies for the treatment of SFA occlusive diseases and popliteal artery aneurysm supported with an unrestricted educational grant by Gore &amp; Associates</td>
</tr>
<tr>
<td>11:05 – 12:15</td>
<td>Next generation dual component stent design: Concept and early clinical experience in the SFA</td>
</tr>
<tr>
<td>12:15 – 12:30</td>
<td>Discussion and conclusion by the chairman</td>
</tr>
<tr>
<td>11:35 – 11:45</td>
<td>Versatility of GORE® VIABAHN® in treating vascular diseases</td>
</tr>
<tr>
<td>11:00 – 11:05</td>
<td>Introduction by the chairman</td>
</tr>
</tbody>
</table>

We are asking all faculty members to strictly respect the given time limits.